Eye therapy
AssigneeAvedro, Inc.
InventorsDavid Muller, John Marshall, Marc D. Friedman
Life of this patent
Estimating the term…
Loading patent…
AssigneeAvedro, Inc.
InventorsDavid Muller, John Marshall, Marc D. Friedman
Estimating the term…
Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.
A system for controlling cross-linking in corneal tissue, comprising:
A system for controlling cross-linking in corneal tissue, comprising:
A system for controlling cross-linking in corneal tissue, comprising:
Dependencies are inferred from the claim text.